Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis
- 1 January 2019
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 133, 74-83
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81270591, 81470346, 81670132)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Qinglan Project of Jiangsu Province of China (BE2016665)
This publication has 40 references indexed in Scilit:
- Clonal diversity of recurrently mutated genes in myelodysplastic syndromesLeukemia, 2013
- Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disordersLeukemia, 2012
- Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessBlood, 2011
- Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromesNature Genetics, 2011
- SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implicationsLeukemia, 2011
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsNew England Journal of Medicine, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- The Spliceosome: Design Principles of a Dynamic RNP MachineCell, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986